Author:
Touzeau C,Moreau P,Dumontet C
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference104 articles.
1. Dimopoulos MA, Richardson PG, Moreau P, Anderson KC . Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 2015; 12: 42–54.
2. Moreau P, Touzeau C . Multiple myeloma: from front-line to relapsed therapies. ASCO Educ Rev 2015, e504–e511.
3. Tagde A, Rajabi H, Bouillez A, Alam M, Gali R, Bailey S et al. MUC1-C drives MYC in multiple myeloma. Blood 2016; 127: 2587–2597.
4. Burton J, Mishina D, Cardillo T, Lew K, Rubin A, Goldenberg DM et al. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. Clin Cancer Res 1999; 5: 3065s–3072s.
5. Carmon L, Avivi I, Kovjazin R, Zuckerman T, Dray L, Gatt ME et al. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol 2015; 169: 44–56.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献